Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by mikeq113on May 13, 2020 4:06pm
132 Views
Post# 31024219

RE:Down 30+% since hitting $4.17

RE:Down 30+% since hitting $4.17Juniper88, I think you are absolutely correct. If you recall, RetiredRIA also mentioned he suspected that several high net worth individuals that he knew could have been building a position in that run-up as well. The story seems to continue to be that THTX is struggling to make a compelling case to the market - institutional or retail. We've seen essentially anemic volume in the days since hitting our previous peak around April 23rd or so and thus, are subject to the whims of the few on any given day.

The silver lining here is that it will take just as few individuals or even one institution to move the price just as quickly in the right direction for us on the heels of positive news, IF management can create that positive narrative and excitement around the upcoming trial.

It's days like these that I keep reminding myself of Wino's loaded spring!
Bullboard Posts